FeRx evaluates drug delivery technology for cancer:
This article was originally published in Clinica
FeRx is receiving a grant from the US National Cancer Institute of the National Institutes of Health to assess the effectiveness of its microparticle drug delivery system for treating pancreatic cancer. The San Diego, California firm will evaluate the use of its MagneTarg technology for the targeted delivery of the drug gemcitabine. The microparticles are made of metallic iron and activated carbon and are drawn to the tumour site using a magnetic field.